Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091375 · ClinicalTrials.gov registry record · Phase 3
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT02091375 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 120 participants.
The verdict
NCT02091375, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
Interventions
- DRUG Placebo control
- DRUG GWP42003-P 20 mg/kg/day Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-03-30 |
| Est. Completion | 2015-11-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091375
The ClinicalTrials.gov registry entry for NCT02091375 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.
NCT02091375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02091375 about?
NCT02091375 is a clinical study titled "Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)". To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
What is the current status of trial NCT02091375?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2015-03-30. Estimated completion is 2015-11-26.
What interventions are being tested in trial NCT02091375?
The interventions under investigation include: Placebo control (DRUG), GWP42003-P 20 mg/kg/day Dose (DRUG).
Who is sponsoring clinical trial NCT02091375?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.